ANI Pharmaceuticals, Inc. unveiled significant preclinical findings on its Purified Cortrophin Gel at the EULAR 2025 Congress in Barcelona. The study highlights the gel’s potential in reducing inflammation and joint swelling in rheumatoid arthritis models.
Breakthrough in Arthritis Management
Dr. Mary Pao, ANI’s Chief Medical Officer, emphasized that the research demonstrated a notable decrease in inflammatory cytokines without adverse effects on bone integrity. Conducted using a murine collagen-induced arthritis model, the study tested varying doses of the gel, observing a dose-dependent reduction in joint swelling.
Collaboration Enhances Research Quality
Led by esteemed professors from the University of California, the study underscores ANI’s dedication to advancing scientific and clinical research. The collaboration with top-tier scientists aims to deepen the understanding of Cortrophin Gel’s mechanisms, potentially benefiting a broader patient base.
- Purified Cortrophin Gel effectively reduces joint inflammation in preclinical models.
- High-dose administration shows enhanced efficacy without compromising bone health.
- Findings support further clinical trials for rheumatoid arthritis treatment.
The study’s presentation at EULAR 2025 marks a pivotal moment for ANI Pharmaceuticals, reinforcing its commitment to developing innovative therapies for rare and chronic diseases.
Cortrophin Gel, administered subcutaneously, is already approved for short-term use in acute rheumatoid arthritis cases. These new findings could pave the way for expanded indications and improved patient outcomes.
ANI Pharmaceuticals continues to prioritize research and development, ensuring that its therapeutic solutions meet the evolving needs of patients worldwide. The company’s focus on rare diseases positions it as a key player in the biopharmaceutical industry.
Advancements like these not only enhance treatment options but also provide hope for individuals battling debilitating autoimmune conditions. As ANI Pharmaceuticals progresses, stakeholders can anticipate further breakthroughs that align with the company’s mission to improve lives through innovative medicine.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
